SkinBioTherapeutics has provided a trading and business update, detailing progress for its two lead programmes and also its earlier stage oral health programme. For AxisBiotix-PS, the company has announced revenues generated over the first 8-monhts of launch of £75k and, significantly, improving subscriber retention rates of 85%+. SkinBioTherapeutics is engaged with a number of global multinational companies with a view to securing an exclusive deal for the AxisBiotix product. Early results from ....
31 Aug 2022
Cenkos:SkinBioTherapeutics Plc - Trading update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos:SkinBioTherapeutics Plc - Trading update
SkinBioTherapeutics Plc (SBTX:LON) | 9.2 0 (-5.1%) | Mkt Cap: 18.5m
- Published:
31 Aug 2022 -
Author:
Chris Donnellan -
Pages:
6
SkinBioTherapeutics has provided a trading and business update, detailing progress for its two lead programmes and also its earlier stage oral health programme. For AxisBiotix-PS, the company has announced revenues generated over the first 8-monhts of launch of £75k and, significantly, improving subscriber retention rates of 85%+. SkinBioTherapeutics is engaged with a number of global multinational companies with a view to securing an exclusive deal for the AxisBiotix product. Early results from ....